Samelis Georgios F, Ekmektzoglou Konstantinos, Tsiakou Andriani, Giannakaki Styliani, Konstadoulakis Manoussos
Oncology Department, University of Athens, Medical School, Greece.
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1776-81. doi: 10.5754/hge10455. Epub 2011 Jul 15.
BACKGROUND/AIMS: Although research on new effective treatments against pancreatic cancer is intense, limited therapeutic schemes are currently approved. The aim of the present study was to record the efficacy and safety of gemcitabine-erlotinib plus docetaxel combination therapy in patients with advanced and/or metastatic pancreatic cancer.
Twenty-five chemotherapy naive patients with histologically confirmed unresectable pancreatic cancer and documented extrapancreatic metastases, received biweekly gemcitabine 1,500mg/m2 during a 28-day long cycle; daily erlotinib 100mg per os; and docetaxel 80mg/m2 as intravenous infusion administered every 15 days. Patients were monitored every 4 cycles for survival, adverse events and tumour response with Computed Tomography scans.
Patients received 153 cycles in total, with a median of 7.64 cycles (range, 1-24). The median overall survival was 10 months and 45% of the patients reached and surpassed 1-year survival. No grade IV toxicities were recorded. The only grade III recorded toxicities were thrombopenia (4 patients, 16%), anaemia (1 patient, 4%) and neutropenia (1 patient, 4%). Overall the most frequently experienced adverse events were grade I anaemia (18 patients, 72%) and grade II rash (13 patients, 52%).
Biweekly gemcitabine with erlotinib plus docetaxel administration is a practical alternative to pancreatic cancer treatment, presenting comparable results to weekly gemcitabine administration.
背景/目的：尽管针对胰腺癌的新型有效治疗方法的研究十分密集，但目前获批的治疗方案有限。本研究的目的是记录吉西他滨-厄洛替尼联合多西他赛治疗晚期和/或转移性胰腺癌患者的疗效和安全性。
25例未经化疗且经组织学确诊为不可切除胰腺癌并有胰腺外转移记录的患者，在为期28天的周期中每两周接受一次1500mg/m²的吉西他滨治疗；每天口服100mg厄洛替尼；每15天静脉输注一次80mg/m²的多西他赛。每4个周期对患者进行生存、不良事件监测，并通过计算机断层扫描监测肿瘤反应。
患者共接受153个周期治疗，中位周期数为7.64个周期（范围1-24）。中位总生存期为10个月，45%的患者达到并超过1年生存期。未记录到IV级毒性反应。仅记录到的III级毒性反应为血小板减少（4例患者，16%）、贫血（1例患者，4%）和中性粒细胞减少（1例患者，4%）。总体而言，最常出现的不良事件为I级贫血（18例患者，72%）和II级皮疹（13例患者，52%）。
每两周给予吉西他滨联合厄洛替尼及多西他赛是胰腺癌治疗的一种实用替代方案，其结果与每周给予吉西他滨相当。
